<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400165</url>
  </required_header>
  <id_info>
    <org_study_id>REB-2010023</org_study_id>
    <nct_id>NCT01400165</nct_id>
  </id_info>
  <brief_title>Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations</brief_title>
  <official_title>Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ottawa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generic describes a pharmaceutical product that does not have a brand name or trademark.
      Generic medications should be the equivalent of brand medications. Only their price should be
      different. The active ingredient of the generic medication has to be within a window of 80 to
      125% of the original in the blood. There are reports that this standard is not always
      followed after the medication has been on the market. Indeed, it was observed that some
      patients previously stable on original medications relapsed when switched to a generic.
      Several factors could account for this problem. Such problems have been reported for
      Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and
      the original brands will be examined for these three medications. The three original
      medications used in this study are the Visken, the Seroquel, and the Desyrel. The three
      generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all
      available on the Canadian market by prescription.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of Medication</measure>
    <time_frame>0 to 48 hours after drug ingestion</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Desyrel/Teva-Trazodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visken/Teva-Pindolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seroquel/Teva-Quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)</description>
    <arm_group_label>Desyrel/Teva-Trazodone</arm_group_label>
    <other_name>Desyrel</other_name>
    <other_name>Teva-Trazodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)</description>
    <arm_group_label>Seroquel/Teva-Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
    <other_name>Teva-Quetiapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pindolol</intervention_name>
    <description>each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)</description>
    <arm_group_label>Visken/Teva-Pindolol</arm_group_label>
    <other_name>Visken</other_name>
    <other_name>Teva-Pindolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.</description>
    <arm_group_label>Desyrel/Teva-Trazodone</arm_group_label>
    <arm_group_label>Visken/Teva-Pindolol</arm_group_label>
    <arm_group_label>Seroquel/Teva-Quetiapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers (absence of diseases: psychiatric, physical, neurological,
             metabolic,...)

        Exclusion Criteria:

          -  Psychiatric disorder

          -  Hepatic disease

          -  Renal disease

          -  Gastrointestinal disease

          -  Hematological disease

          -  Smokers

          -  Physical and/or neurological disease

          -  Positive urine drug screen

          -  Abnormal blood pressure

          -  Abnormal Electrocardiogram

          -  Abnormal urine/blood analysis (sodium, potassium, chloride, creatinine, urea, ALT,
             AST, total protein, glucose, and TSH)

          -  Taking medication

          -  Have donated 50 mL to 499 mL whole blood within 30 days and more than 499 mL whole
             blood within 56 days preceding entry into this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Blier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa, Institute of Mental Health Research - Mood Disorders Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck Chenu, PharmD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa, Institute of Mental Health Research - Mood Disorders Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre BLIER, MD, PhD</last_name>
    <phone>613-722-6521</phone>
    <phone_ext>6041</phone_ext>
    <email>pierre.blier@rohcg.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Fusee, RN</last_name>
    <phone>613-722-6521</phone>
    <phone_ext>7828</phone_ext>
    <email>wendy.fusee@rohcg.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa, Institute of Mental Health Research</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z-7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Chenu, PharmD, PhD</last_name>
      <phone>613-722-6521</phone>
      <phone_ext>6041</phone_ext>
      <email>franck.chenu@rohcg.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Fusee, RN</last_name>
      <phone>613-722-6521</phone>
      <phone_ext>7828</phone_ext>
      <email>wendy.fusee@rohcg.on.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Pierre BLIER, MD, PhD</name_title>
    <organization>University of Ottawa, Institute of Mental Health Research - Mood Disorders Research Unit</organization>
  </responsible_party>
  <keyword>Therapeutic Equivalency</keyword>
  <keyword>Human Experimentation</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Brand name</keyword>
  <keyword>Generic</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Trazodone</mesh_term>
    <mesh_term>Pindolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

